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Abstract
Background: At present, diabetes is a chronic disease of great cost and heavy burdens. The International Diabetes
Federation has repeatedly warned that by 2025, the global number of diabetics would rise to 333 million from 194
million in 2003. Although the occurrence of diabetes in developing countries is lower, China has a large population,
so that the number of cases is increased. At the same time, more people have prediabetes, a growing health
concern where a large percentage of the patients develop full type 2 diabetes. In addition, the patients of diabetes
easily incur complications such as blindness, kidney failure, and cardiovascular diseases that can seriously affect the
patients’ quality of life and cause great economic burdens to family and society. Therefore, effective interventions
for prediabetes are needed to prevent or delay the occurrence and development of diabetes.
Methods: A randomized controlled trial that was assessed with pharmacoeconomic methods was undertaken in
this study. The study term was 24 months (12 months for the intervention and 12 months for follow up). Four
hundred participants, recruited from four cities in China: Beijing, Tianjin, Xian, and Naning, were randomized to the
treatment group (JQJT tablets) and the control group (placebo). Participants included in this study had been
diagnosed with prediabetes according to the criteria for western medicine and Traditional Chinese Medicine (TCM).
The end-point effectiveness indexes included the incidence of diabetes and the reversion rate. The drug costs and
lifestyle intervention costs were included in the total costs. The study used the cost-effectiveness analysis to discuss
the economic advantage of the JQJT tablets.
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Results: The outcomes of the study contained 2 sections,namely clinical outcomes and cost-effectiveness analysis
outcomes. The clinical outcomes: the treatment group and control group had no significant statistical difference
P> 0.05) on the baseline of situation; Jinqi Jiangtang tablet effectively reduced the incidence of diabetes mellitus
and enhanced reversion rate. compared with the control group (p< 0.05); the scores of SF-36 of two groups had
no significant difference P> 0.05); finally the compliance of participants between the two groups had no signicant
difference. The cost-effectiveness analysis outcomes:in the intervention period of 12 months,on the aspect of
reversion rate, the treatment group had better economic advantage by using cost-effectiveness ratio and the
incremental cost-effectiveness ratio;on the aspect of the incidence of diabetes, the control group had better
economic advantage by using cost-effectiveness ratio and the incremental cost-effectiveness ratio; in the
follow-up peiod of 24 months, on the aspect of reversion rate, the treatment group had better economic
advantage by using cost-effectiveness ratio and the incremental cost-effectiveness ratio, on the aspect of the
incidence of diabetes, the control group had better economic advantage by using cost-effectivenes ratio and the
incremental cost-effectiveness ratio.At the same time, these outcomes remained the same by sensitivity analysis.
Assuming that prices and resident incomes rose 5%, the sensitiveness analysis shows that the two group affected
by the paremeters changed little.
Conclusion: The importance and effectiveness of lifestyle education and JinQi Jiangtang tablets was proven. In
both the intervention period and follow-up, JinQi Jiangtang tablets combined with lifestyle education had a
greater cost advantage effect than the lifestyle education alone on the reversion rate; the lifestyle education had a
greater cost advantage effect than the JinQi Jiangtang tablets combined with lifestyle education on the incidence
of diabetes.
Trial registration: Chinese Clinical Trials ChiCTR-TRC-09000401) , registered on 25 May 2009.
Keywords: Cost-effectiveness analysis, JinQi Jiangtang tablets, Prediabetes
Background
At present, diabetes is a chronic disease that incurs great
costs and heavy burdens. The International Diabetes Fed-
eration has repeatedly warned that by 2025, the global
number of diabetes cases will have risen to 333 million
from 194 million in 2003. In China, the number of dia-
betes cases will be 46 million, and the diabetes burden will
be expected to 450.1 billion yuan. Some studies have dis-
covered that about 5 % to 10 % of prediabetes will develop
into diabetes within 1 year. Therefore, effective interven-
tions for patients with prediabetes that can prevent and
delay the occurrence or development of diabetes, thereby
incurring an economic advantage, is necessary.
Prevention and treatment on prediabetes in lifestyle and
Traditional Chinese Medicine
The Daqing study from 1986 to 1994 discovered that
lifestyle interventions could decrease the incidence of
diabetes by 30 % to 50 % [1]. Nineteen randomized con-
trolled trials, which included a systematic evaluation of
prediabetes interventions, showed that the combination
of lifestyle and Chinese medicine intervention was able
to decrease fasting blood glucose in 1471 cases. Further-
more, the 2-hour postprandial insulin levels and 2-hour
postprandial blood glucose levels were lower than ob-
served with simple lifestyle intervention [2]. Therefore, a
combination of lifestyle and Traditional Chinese Medicine
(TCM) interventions offer possibilities for the effective
prevention of prediabetes.
Pharmacodynamics and preclinical use of JinQi
Jiangtang tablets
Pharmacodynamics and preclinical use of JQJT tablets, pro-
duced by Coptis, Astragalusand Honeysuckle, suggested
that the tablets could be beneficial for the treatment of pre-
diabetes. Regarding aspects of pharmacodynamics, some
studies have proven that the tablets can affect glycometabo-
lism, insulin resistance (IR), and serum insulin, as well as
immune function [3–5]. On the other hand, Shen Zhufang
discovered that JQJT tablets can improve insulin resistance
in humans [6]. Zhang Rongrong indicated that JQJT tablets
can delay the development of diabetic nephropathy and
prevent progression from prediabetes to diabetes [7].
Methods
Objective
The objective of this study was to evaluate the effective-
ness,safety, and economic advantage of JQJT tablets for
prediabetes in China by comparison with a placebo.
Research type
This was a randomized, controlled, double-blind clinical
trial. Ethical approval was given by the Chinese Ethics
Committee for Registering Clinical Trials (ChiECRCT)
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with the following reference number: ChiECRCT-
20090009. The trial was registered at the Chinese Clinical
Trial Registry (Registration ID:ChiCTR-PRC-09000401),
and the protocol, the informed consent form, and other
relevant documents were reviewed and approved by its af-
filiated Ethics Review Committee. The Tianjin University
of Traditional Chinese Medicine was held responsible for
the organization and coordination of the trial sites and
staff. The participating institutions included the First
Hospital of Peking University, the Second Affiliated
Hospital of Tianjin University of TCM, the Metabolic
Diseases Hospital of Tianjin Medical University, the
first Affiliated Hospital of Guangxi Medical University
and Xijing Hospital.
Randomized controlled trial
The randomization of the trial was completed by the in-
dependent data center Interact Voice Responding
System (IVRS). According to a random sequence table
(generated by SAS 8.2), patients who conformed to the in-
clusion criteria were allocated randomly into one of the
two groups in a ratio of 1:1. The identification code and
random number, which were unique for each patient, were
generated by the IVRS. This study was designed to be
double blind. After the database was closed, the person in
charge of the blind code delivered an allocation schedule
designated only as groups A and B to the statistics depart-
ment. Then, after receiving the statistical outcome and
final report, the person in charge of the blind code
declared the real meaning of groups A and B.
Ethics
The study was conducted in abidance with Chinese clin-
ical trial quality control standards and in accordance
with the Declaration of Helsinki.
Ethical approval
Ethical approval was given by the Chinese Ethics Com-
mittee for Registering Clinical Trials (ChiECRCT) with
the following reference number ChiECRCT-20090009.
Ethics committee
Before the beginning of the study, all hospitals provided
related data about the qualifications of the main re-
searcher and the laboratory conditions in order to assist
the ethics committee with their decision to allow the
trial. The individual units were not required to request
ethics approval again unless for a special request, and
they were able to contact the ethics committee and state
their request if necessary.
Informed consent form
The informed consent form (ICF) was reviewed and ap-
proved by the ethics committees before the study
commenced. Researchers informed participants of the rele-
vant information in words and writing in clearly under-
standable language. The ICF was signed and dated by the
participants or their representatives. Before signing the ICF,
the participants and their representatives were allowed ad-
equate time to read the form. The signed ICFs were main-
tained independently by the researchers and participants.
Screening of the participants
The 400 prediabetes patients who were included accord-
ing to the diagnosis criteria and inclusion criteria (see
the next section) were divided into the treatment group
and control group (1:1). All the participants signed the
informed consent form.
Intervention
For lifestyle intervention, the study team developed an in-
dividual diet program for each participant to ensure a rea-
sonable proportion of carbohydrates, protein, and calories.
In addition, the recommended diet was low in sugar and
low in salt, and the program advised the participants to
give up some bad habits. Smoking and alcohol consump-
tion were strictly controlled. An exercise program was for-
mulated for the participants according to age and sex.
The drug intervention covered a period of 12 months.
All participants had to visit the researchers each month.
The JQJT tablets for the treatment group required that
the participants take seven tablets twice daily, and all
drugs were taken before meals. The control group re-
ceived a placebo, and the method and time were the
same as for the treatment group.
The model
The diagnosis criteria (The Diagnosis and Classification
of Diabetes Mellitus, ADA 2008) [8] included impaired
fasting glucose (IFG) (FPG 5.6 to 6.9 mmol/L) and/or
impaired glucose tolerance (IGT)(FPG < 5.6 mmol/L and
OGTT (oral glucose tolerance test) 2hPG (2-hour
plasma glucose) 7.8 to 11.1 mmol/L).
To meet the inclusion criteria, the potential partici-
pant must have fulfilled the prediabetes diagnostic cri-
teria, be 30 to 70 years of age, and have completed and
submitted the informed consent form.
Exclusion criteria included a the history of diabetes
(except gestational diabetes); recent cardiovascular
events (severe organic heart disease, specific angina, type
II degree atrioventricular block, etcetera); impaired hep-
atic and renal function; endocrine disease (cancer, hyper-
thyroidism, etcetera); former use of glucocorticoid,
thiazide diuretics or nicotinic acid; pregnancy, prepar-
ation for pregnancy or currently lactating; suffering from
mental diseases or non-cooperative as a patient; partici-
pated in other clinical trial within the last two weeks; or
refusing to provide consent for the study.
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Rejection criteria included failure to take medicine ac-
cording to the protocol or incomplete data.
Suspension criteria included poor compliance; ser-
ious adverse events; complications and special physio-
logical changes; abnormal unblinding; reluctance to
continue the study; taking medicine forbidden in the
study; or if national laws, the Ministry of Science and
Technology, or other authorities decided to terminate
the study, etcetera.
Follow-up
The intervention period was 12 months, with partici-
pants checking in once a month for 12 months; after
the intervention, the 12-month follow-up began and
included check-ins in the 2nd, 6th, and 12th month
after intervention.
Outcome measures
The primary outcome was the occurrence of type 2 dia-
betes (according to the guidelines of the ADA, 2008)
and blood glucose change to normal (FPG < 5.6 mmol/L
and OGTT 2hPG < 7.8 mmol/L).
The secondary outcome was the score of the Short
Form 36 Health Survey Questionnaire (SF −36).
Compliance was measured in participants according to
the following procedure: researchers gave the investiga-
tional drugs to inpatients and explained the methods for
using the medication to the outpatient. The compliance of
the participants was determined by inspection of the
remaining drugs and notes on the number remaining. The
participants were asked to bring the drugs to the final visit
to allow calculation of the number of tablets used.
The SF-36 was used as a measure of compliance; dur-
ing the drug intervention, participants were required to
complete five SF-36 forms, and in the follow-up, they
were required to complete three forms. According to the
clinical effects of the individual treatment, the actual
number of forms completed differed.
Measures for the costs included the drug costs and life-
style intervention costs. Lifestyle intervention costs con-
sisted of lifestyle education materials costs (2.5 yuan per
person for 24 months, 2 yuan per person in the interven-
tion period), lifestyle education meeting costs (1220 yuan
every meeting, with 80 meetings held during the drug
intervention period and 150 meetings being held during
the entire trial), and the costs of participants compliance
(30 minutes to fill in the SF-36 form and 2 hours for lis-
tening to meetings. The current average monthly income
of urban residents is 2400 yuan or 10 yuan per hour,
which was used to calculate the cost of time).
The safety index includes a general medical examin-
ation; blood and urine tests during the study visits; func-
tional examinations to determine EKG, ALT, BUN, and
Cr; and adverse events.
Model input data
The evaluation criteria of the efficacy of the treatment
on the diabetes conversion rate was based on The Diag-
nosis and Classification of Diabetes Mellitus, ADA 2008.
Incidence of diabetes mellitus ¼ cases of diabetes mellitus
total cases of eachgroup 100%
The rate of blood glucose return to normal (refer to
the Diagnosis and Classification of Diabetes Mellitus,
ADA 2008)
Reversion rate ¼ cases of blood glucose return to normal
total cases of each group 100%
Compliance of participants
Compliance ¼ ½ðdispensed  remainingÞ  dispensed  100%
The score of the SF-36
The SF-36 questionnaire was used to evaluate the vari-
ous dimensions and entries, and between-group and
within-group comparisons were made of the total score
of the questionnaire. The score was calculated with
measurement data.
Costs
The drug costs ¼ ðdispensed  remainingÞ 
price per tablet  compliance
The lifestyle intervention costs
¼ ðlifestylee ducation materials costsþ
lifestyle education meetings costs þ
the costs of participants complianceÞ 
compliance of filling in the SF36
the score of SF36
The cost-effectiveness ratio
The incidence of diabetes mellitus was used to represent
the clinical effectiveness index:
the costeffectiveness ratio ¼ the total costs
incidence of diabetes mellitus
the costeffectiveness ratio ¼ the total costs
reversion rate
Statistical methods
For between-group comparisons, the following statistical
tests were used: the chi-square test for enumeration
data, the Wilcoxon rank sum test for non-normal
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distribution of measurement data, and the t-test for
normal distribution of measurement data.
For dropping analysis, the chi-square test or Fisher
exact probability method was used.
For compliance analysis, the chi-square test or Fisher
exact probability method was used.
Clinical outcomes and cost-effectiveness analysis
This clinical trial screened 400 patients, and 376 cases
were qualified for inclusion. Ultimately, 362 cases were
randomly assigned, with 182 cases in the treatment
group and 180 cases in the control group. Adverse
events in the treatment group and the control group
occurred in five cases and three cases, respectively, so
the incidences of adverse events were 2.78 % and 1.65 %.
No statistically significant difference was observed be-
tween the two groups because there were no drug-
related adverse reactions.
Clinical outcomes
As shown in Tables 1, 2 and 3, the treatment group and
control group showed no statistically significant differ-
ence (P > 0.05) at baseline for sex, marital status, nation-
ality, height, weight, profession, history of disease, past
medical history, blood sugar levels, values of OGTT, and
so on. Only the baseline data for age showed slight
Table 1 Comparison between the treatment group and control group in the baseline information
Baseline information Index The total cases The control group The treatment group
Age N 362(0) 180(0) 182(0)
Mean 54.49(8.78) 53.49(8.85) 55.49(8.61)
Statistical Wilcoxon rank sum test:-2.096
P 0.036
Gender Male n (%) 172(47.51 %) 82(45.56 %) 90(49.45 %)
Female n (%) 190(52.49 %) 98(54.44 %) 92(50.55 %)
N 362(0) 180(0) 182(0)
Statistical the Chi-square test:0.551
P 0.458
Marital status Unmarried n (%) 4(1.10 %) 2(1.11 %) 2(1.10 %)
Married n (%) 358(98.90 %) 178(98.89 %) 180(98.90 %)
N 362(0) 180(0) 182(0)
Statistical Fisher exact probability method
P 1.000
Height N 362(0) 180(0) 182(0)
Mean 165.27(7.85) 165.17(7.65) 165.35(8.07)
Statistical Wilcoxon rank sum test:-0.205
P 0.837
Weight N 362(0) 180(0) 182(0)
Mean 67.78(11.64) 67.49(11.21) 68.06(12.08)
Statistical Wilcoxon rank sum test:-0.062
P 0.837
Profession Worker n (%) 100(27.62 %) 49(27.22 %) 51(28.02 %)
Farmer n (%) 29(8.01 %) 14(7.78 %) 15(8.24 %)
Intellectual n (%) 100(17.62 %) 59(32.78 %) 41(22.53 %)
Students n (%) 0(0.00 %) 0(0.00 %) 0(0.00 %)
Retirement n (%) 94(25.97 %) 41(22.78 %) 53(29.12 %)
Unoccupied n (%) 11(3.04 %) 4(2.22 %) 7(3.85 %)
Other n (%) 28(7.73 %) 13(7.22 %) 15(8.24 %)
N 362(0) 180(0) 182(0)
Statistical the Chi-square test:5.797
P 0.327
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differences (P = 0.036).The baseline data between the
two groups were fundamentally equivalent and thus
comparable at baseline.
Tables 4,5 and 6 showed the incidence of diabetes mel-
litus and the reversion rate. During the whole trial
process, 37 cases of the treatment group advanced to
diabetes, 59 cases of the control group advanced to dia-
betes (P < 0.05), therefore, the JinQi Jiangtang tablet ef-
fectively reduced the incidence of diabetes mellitus. In
addition, 82 cases of the treatment group returned to
normal blood glucose, and 54 cases of the control group
returned to normal blood glucose (P < 0.05); therefore,
compared with the control group, the JinQi Jiangtang
tablet effectively enhanced reversion rate.
Tables 7 and 8 showed the lifestyle intervention compli-
ance. The two groups (treatment and control) separately
received 681 SF-36 forms and 694 SF-36 forms, so the ac-
tual recovery rates of the SF-36 forms were 91.04 % and
83 %, respectively, in the intervention period of 12 months.
In the 24-month follow-up period, the two groups separ-
ately received 1073 forms and 1077 forms, so the actual
recovery rates of the SF-36 forms were 96.46 % and
87.37 %, respectively.
Tables 9 and 10 showed the scores of SF-36. Despite
the intervention period of 12 months or the whole
period of 24 months, the average score of the two
groups were more than 65 points, P > 0.05, so they had
no significant difference.
Table 11 showed the level of compliance of the partici-
pants. The compliance rates of the two groups were
more than 80 % (P > 0.05) by rank sum test, so they had
good compliance and no significant difference.
Cost-effectiveness analysis
The costs were calculated according to the following:
1. For the drug costs, when one case advanced to
diabetes mellitus or the blood glucose returned to
normal, the case should have stopped taking
medicine. The market retail price of the JQJT
tablets (24 tablets × 3) was based on each tablet
costing 0.26 yuan. The number of cases
(participants) taking medicine at 3, 6, 9 and
12 months were 54, 27, 13 and 88 cases.
Therefore, costs were determined as shown in the
following equation:
The drugs costs ¼ 7 3 30 3 54þ 7 3 30
 6 27þ 7 3 30 9 13þ 7
 3 30 12 88Þ  0:26 92:94%
¼ 227896:9yuan
2. The lifestyle intervention costs in the 12-month
intervention period were calculated as indicated
below:
The lifestyle intervention costs of the treatment group
¼ 182 2þ 1220 80=2þ 681 5þ 182 2
 10 80Þ  91:04% 66:87 ¼ 20928123:4yuan
The lifestyle intervention costs of the control group
¼ 180 2þ 1220 80=2þ 694 5þ 180 2 10
 80Þ  83% 66:55 ¼ 18815209:0yuan
3. The lifestyle intervention costs in the 24-month
follow-up period were calculated as follows:
The lifestyle intervention costs of the treatment group
¼ 182 2:5þ 1220 150=2 1035 5þ 182 2
10 150Þ  94:46% 67:72 ¼ 41139933:9yuan
The lifestyle intervention costs of the control group
¼ 180 2:5þ 1220 150=2þ 941 5þ 180 2
10 150Þ  87:37% 67:47 ¼ 37529823:2yuan
The cost-effectiveness ratio is addressed in Tables 12
and 13, which showed the cost-effectiveness analysis for
Table 2 Comparison of the history of disease and the past
medical history between the two groups








No n (%) 269(74.31 %) 132(73.33 %) 137(75.27 %)
Yes n (%) 93(25.69 %) 48(26.67 %) 45(24.73 %)






No n (%) 288(79.78 %) 145(80.56 %) 143(79.01 %)
Yes n (%) 73(20.22 %) 35(19.44 %) 38(20.99 %)




Table 3 Comparison between the two groups on fasting
plasma glucose (FPG) and oral glucose tolerance test (OGTT)
2-hour plasma glucose (2hPG) in the screening stage




FPG N 362(0) 182(0) 180(0)
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the 12-month intervention period. The total costs of
the treatment group and the control group were
21,156,020.3 yuan and 1,885,209.0 yuan, respectively,
and in terms of the reversion rate, the cost-
effectiveness ratios were 506,124.9:676,806.1, so the
treatment group was smaller. From the incremental
cost-effectiveness ratio, the control group needed
more than 167,213.7 yuan for each 1 % increase in
the reversion rate to show that the treatment group
had better economic advantages. With regard to the
incidence of diabetes, the cost-effectiveness ratios of
the treatment group and the control group were
1,282,183.0:651045.3, so the control group was smaller.
From the incremental cost-effectiveness ratio, the treat-
ment group needed more than 188,775.1 yuan for each
1 % decrease in the incidence of diabetes, which
showed that the control group had the better eco-
nomic advantage.
Tables 14 and 15 showed the cost-effectiveness ana-
lysis in the 24-month period. The total costs of the treat-
ment group and the control group were 41,367,830.8
yuan and 37,529,823.2 yuan, and with regard to the re-
version rate, the cost-effectiveness ratios were 917,246.8
and 1,250,994.1, respectively, so the treatment group
was smaller. From the incremental cost-effectiveness ra-
tio, the control group needed more than 254,172.7 yuan
for each 1 % increase in the reversion rate to show that
the treatment group had a better economic advantage.
With regard to the incidence of diabetes, the cost-
effectiveness ratios of the treatment group and the con-
trol group were 2,037,824.8 and 1,144,201.0, so the con-
trol group was smaller. From the incremental cost-
effectiveness ratios, the treatment group needed more
than 307,040.6 yuan for each 1 % decrease in the inci-
dence of diabetes, which showed that the control group
had a better economic advantage.
Sensitivity analysis
Cost-effectiveness results were most sensitive to the
drug prices and resident incomes. Assuming that prices
and resident incomes rose 5 %, the sensitivity analysis
shows that the two group affected by the parameters
changed little (Tables 16, 17, 18, and 19).
Results
The outcomes of the study contained two sections,
namely, clinical outcomes and cost-effectiveness analysis
outcomes.
The clinical outcomes revealed that the treatment group
and control group showed no significant statistical differ-
ences (P > 0.05) in baseline values. The JinQi Jiangtang tab-
let effectively reduced the incidence of diabetes mellitus
and enhanced the reversion rate. Compared with the con-
trol group (P < 0.05), the scores of the SF-36 of the two
groups showed no significant difference (P > 0.05), and the
compliance of participants showed no significant difference
between the two groups.
With regard to the cost-effectiveness analysis out-
comes, in the 12-month intervention period, for rever-
sion rate, the treatment group had a better economic
advantage according to the cost-effectiveness ratio and
the incremental cost-effectiveness ratio. Regarding the
incidence of diabetes, the control group had a better
economic advantage according to the cost-effectiveness
ratio and the incremental cost-effectiveness ratio. In the
24-month period, with regard to the reversion rate, the
treatment group had a better economic advantage ac-
cording to the cost-effectiveness ratio and the incremen-
tal cost-effectiveness ratio, and for the incidence of
diabetes, the control group had a better economic ad-
vantage according to the cost-effectiveness ratio and the
incremental cost-effectiveness ratio. Furthermore, these
outcomes remained the same when assessed with
Table 4 The distribution of the numbers of cases in the 12-month intervention period
Group Month 3 Month 6 Month 9 Month 12
NBG DM FO NBG DM FO NBG DM FO NBG DM FO
The treatment group 37 8 9 20 5 2 7 6 0 12 11 1
The control group 25 23 9 18 13 5 1 5 2 6 11 0
NBG normal blood glucose cases, DM diabetes mellitus cases, FO fall off cases
Table 5 The incidence of diabetes mellitus and reversion rate in
the 12-month intervention period












30 16.5 % 76 41.8 %
The control
group
52 28.9 % 50 27.8 %
Table 6 The incidence of diabetes mellitus and the reversion












37 20.3 % 82 45.1 %
The control
group
59 32.8 % 54 30 %
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sensitivity analysis. Assuming that prices and resident in-
comes rose 5 %, the sensitivity analysis shows that the
two groups affected by the parameters changed little.
Discussion
JinQi Jiangtang tablets have been confirmed as being a
safe and effective modern drug for use in Traditional
Chinese Medicine by clinical research in China and
France, which was based on traditional prescription and
optimized the modern pharmacology experimental
methods. The JQJT tablets, composed by Coptis,
Astragalusand Honeysuckle, show comprehensive treat-
ment effects, such as decreasing blood pressure, serum
lipids, and blood glucose; improving glucose tolerance;
and when compared with a single antihypertensive, de-
creasing blood pressure. DPP, DREAM, and other large
international clinical trials have confirmed that lifestyle
intervention plays a very important role in the preven-
tion of diabetes. Therefore, combining lifestyle interven-
tion and Traditional Chinese Medicine intervention can
achieve better effects, and this combination is easily ac-
cepted by patients. A foundation of good clinical screen-
ing; the use of prescriptions generally accepted as
effective; and carrying out randomized, double-blinded,
multicenter clinical research with large sample size are
necessary. In addition, an evaluation of clinical medicine
should consider three aspects, namely, safety, effective-
ness, and economy. At the same time, the use of phar-
macoeconomic evaluation started late in China, and the
available TCM literature is insufficient; therefore, an
economic evaluation standard is lacking. Obviously, in
order to reveal the security, effectiveness and economy
of the JQJT tablets combined with lifestyle intervention
on the prevention and treatment of diabetes and to pro-
vide a basis for health decisions, it is necessary to ex-
plore a feasible evaluation method.
An evaluation of the cost-effectiveness of JinQi
Jiangtang tablets for the prevention and treatment of
diabetes was conducted using pharmacoeconomics com-
bined with a parallel clinical trial of economics research.
This study evaluated the efficiency and security of TCM,
as well as the pharmaeconomics. This clinical trial
screened 400 patients and identified 376 qualified cases.
Ultimately, 362 cases were randomly assigned, with the
treatment group receiving 182 cases and the control re-
ceiving 180 cases. The treatment group and the control
group both received lifestyle education intervention, and
then separately received JQJT tablets (treatment group)
or JQIT simulation tablets (control). The two groups
showed no significant statistical difference at baseline for
sex, marital status, nationality, height, weight, profession,
history of disease, past medical history, blood sugar
levels, values of OGTT, and so on. The baseline data be-
tween the two groups were fundamentally equivalent
and had baseline comparability. Adverse events occurred
separately in the treatment group and the control group
in five cases and three cases, respectively, so the inci-
dences of adverse events were 2.78 % and 1.65 %. No
statistically significant difference was observed between
the two groups because there were no drug-related ad-
verse reactions. At the same time, for the participants of
the two groups, the study analyzed the clinical curative
effect and the pharmacoeconomic aspects.
The use of cost-effectiveness analysis and incremental
cost-effectiveness analysis revealed that the main cost
of the treatment group included the drug cost and
lifestyle education cost, and for the control group, the
lifestyle education cost. With regard to the clinical
outcomes, the incidence of diabetes mellitus and re-
version rate were included. In the 12-month interven-
tion period, the total costs of the two groups
(treatment and control) were 21,156,020.3 yuan and
1,885,209.0 yuan, whereas the reversion rate and the
incidence of diabetes were separately 41.8 % and
27.8 % and 16.5 % and 28.9 %. Therefore, the cost-
effectiveness ratios were 506,124.9:676,806.1 and
1,282,183.0:651,045.3. The incremental cost-effectiveness
analysis for the control group needed more than 167,213.7
yuan for each 1 % increase, and for the treatment group,
more than 188775.1 yuan for each 1 % decrease in the









The treatment group 681 620 91.04
The control group 694 576 83.00
Table 8 The lifestyle intervention compliance in the whole








The treatment group 1073 1035 94.46
The control group 1077 941 87.3
Table 9 The scores of SF-36 in the 12-month intervention period
Group x  S t P
The treatment group 66.87 ± 6.45 −0.781 0.435
The control group 66.55 ± 6.08
Table 10 The scores of SF-36 in the 24-month period
Group x  S t P
The treatment group 67.72 ± 6.06 −0.397 0.691
The control group 67.47 ± 5.53
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Table 11 Compliance of the participants
Group x  S Z P
The treatment group 92.94 ± 7.28 −0.771 0.441
The control group 92.27 ± 8.29
Table 12 The cost-effectiveness analysis in the 12-month
intervention period (reversion rate)
Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 21156020.3 41.8 506124.9
The control group 18815209.0 27.8 676806.1 167213.7
Table 13 The cost-effectiveness analysis in the 12-month
intervention period (the incidence of diabetes)
Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 21156020.3 16.5 1282183.0 −188775.1
The control group 18815209.0 28.9 651045.3
Table 14 The cost-effectiveness analysis in the 24-month period
(reversion rate)
Group C(yuan) E (%) C/E ΔC/ΔE
The treatment group 41367830.8 45.1 917246.8
The control group 37529823.2 30 1250994.1 254172.7
Table 15 The cost-effectiveness analysis in the 24-month period
(the incidence of normal blood glucose)
Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 41367830.8 20.3 2037824.8 −307040.6
The control group 37529823.2 32.8 1144201.0
C the total costs, C/E the cost-effectiveness ratio, ΔC/ΔE the incremental
cost-effectiveness ratio
Table 16 The cost-effectiveness analysis in the 12-month
intervention period (the reversion rate)
Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 22967057.6 41.8 549451.1
The control group 20425193.3 27.8 734719.2 181561.7
Table 17 The cost-effectiveness analysis in the 12-month
intervention period (the incidence of diabetes)
Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 22967057.6 16.5 1391942.9 −204989.1
The control group 20425193.3 28.9 706754.1
Table 18 The cost-effectiveness analysis in the 24-month period
(the reversion rate)
Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 44911142.2 41.1 995812.5
The control group 40740835.2 30 1358027.8 276179.3
Table 19 The cost-effectiveness analysis in the 24-month period
(the incidence of diabetes)
Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 44911142.2 20.3 2212371.5 −333624.6
The control group 40740835.2 32.8 1242098.6
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incidence of diabetes was needed. In the 24-month
period,, the total costs were 481,367,830.8 yuan and
37,529,823.2 yuan, respectively, and the reversion rate and
the incidence of diabetes were separately 45.1 %, 30 % and
20.3 %, 32.8 %. Therefore, the cost-effectiveness ratios
were 917,246.8:1,250,994.1 and 2,037,824.8:1,144,201.0.
For the incremental cost-effectiveness analysis, the control
group needed more than 254,172.7 yuan for each 1 % in-
crease in the reversion rate, and the treatment group
needed more than 307,040.6 yuan for each 1 % decrease
in the incidence of diabetes.
Accordingly, in both the intervention period and the
follow-up, the JinQi Jiangtang tablets combined with
health education had a greater cost advantage effect than
the health education alone on the normal blood glucose,
and the health education had a greater cost advantage
effect than the JinQi Jiangtang tablets combined with
health education on the incidence of diabetes.
Conclusions
By using pharmacoeconomics in combination with a
clinical trial that had adopted a parallel research design
method, the importance and effectiveness of lifestyle
intervention alone, or in combination with JQJT tablets,
in the prevention of diabetes was demonstrated. Not
only did this combination treatment prevent the predia-
betes from turning into diabetes, but also showed that
the intervention could promote normal blood glucose. A
cost-effectiveness analysis and an incremental cost-
effectiveness analysis showed that JQJT tablets combined
with lifestyle intervention offered a better economic ad-
vantage than lifestyle intervention alone for achieving
normal blood glucose. In addition, the security, the cura-
tive effect, and the economic advantages of the JQJT
tablets in preventing prediabetes from turning into dia-
betes have been proven and provide strong support for
the ideas and theories of Traditional Chinese Medicine.
The cost-effectiveness analysis, whether concerned with
the 12-month intervention period or the 24-month
follow-up period, indicated that the lifestyle intervention
had a better economic advantage than the JQJT tablets
combined with lifestyle intervention, which was also
proven by sensitivity analysis, but needs further discussion.
(2×7×3×30×12×1.02=15422.4) (15422.4×20=308448yuan)
In conclusion, effective interventions for prediabetes
offer economic advantages by preventing or delaying the
occurrence or development of diabetes and reduces the
costs associated with complications of diabetes. This
study has proven the necessity and importance of estab-
lishing a model for the economic benefits of TCM.
Demonstrations of the economic benefits of TCM can
promote the process of internationalization of TCM.
This clinical trial had some shortcomings, such as the
sample size, which should have been larger, and a
follow-up period insufficient to clarify the long-term
curative effect and benefits of the JQJT tablets. In
addition, the available literature for TCM pharmacoeco-
nomics evaluation is limited, and the standards for phar-
macoeconomic evaluation are currently being debated in
China. However, the cost-effectiveness analysis is valu-
able to pharmacoeconomics evaluations, even though
the study may need further discussion. This research
provides a valuable reference for pharmacoeconomic
evaluation of TCM and makes a positive contribution to
the standardization of an evidence-based pharmacoeco-
nomic evaluation process for TCM.
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